The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Open accessAbstract
Initially regarded as “epigenetic modifiers” acting predominantly through chromatin remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase or simply deacetylase inhibitors, have since been recognized to exert multiple cytotoxic actions in cancer cells, often through acetylation of non-histone proteins. Some well-recognized mechanisms of HDACI lethality include, in addition to relaxation of DNA and de-repression of gene transcription, interference with chaperone protein function, free radical generation, induction of DNA damage, up-regulation of endogenous inhibitors of cell cycle progression, e.g., p21, and promotion of apoptosis. Intriguingly, this class of agents is relatively selective for transformed cells, at least in pre-clinical studies. In recent years, additional mechanisms of action of these agents have been uncovered. For example, HDACIs interfere with multiple DNA repair processes, as well as disrupt cell cycle checkpoints, critical to the maintenance of genomic integrity in the face of diverse genotoxic insults. Despite their pre-clinical potential, the clinical use of HDACIs remains restricted to certain subsets of T-cell lymphoma. Currently, it appears likely that the ultimate role of these agents will lie in rational combinations, only a few of which have been pursued in the clinic to date. This review focuses on relatively recently identified mechanisms of action of HDACIs, with particular emphasis on those that relate to the DNA damage response (DDR), and discuss synergistic strategies combining HDACIs with several novel targeted agents that disrupt the DDR or antagonize anti-apoptotic proteins that could have implications for the future use of HDACIs in patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Items 201–249 of 249
Wei, Y., Kadia, T. M., Tong, W., Zhang, M., Jia, Y., Yang, H., Hu, Y., Tambaro, F. P., Viallet, J., O'Brien, S. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0032 · Cited by 71
Dai, Y., Chen, S., Wang, L., Pei, X.-Y., Kramer, L. B., Dent, P., & Grant, S. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08591.x · Cited by 70
Self-citationLuo, Z., Pan, Y., Jeong, L. S., Liu, J., & Jia, L. (2012) · Autophagy · doi:10.4161/auto.21484 · Cited by 70
Fiskus, W. C., Wang, Y., Joshi, R., Rao, R., Yang, Y., Chen, J., Kolhe, R. B., Balusu, R., Eaton, K., Lee, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0721 · Cited by 68
Rosato, R. R., Almenara, J. A., Kolla, S. S., Maggio, S. C., Coe, S., Giménez, M. S., Dent, P., & Grant, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0562 · Cited by 67
Self-citationTan, J. Y., Zhuang, L., Jiang, X., Yang, K., Karuturi, K. M., & Yu, Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512719200 · Cited by 65
Shiozawa, K., Nakanishi, T., Tan, M., Fang, H.-B., Wang, W.-C., Edelman, M. J., Carlton, D., Gojo, I., Sausville, E. A., & Ross, D. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1587 · Cited by 64
Dai, Y., Chen, S., Venditti, C. A., Pei, X., Nguyen, T. K., Dent, P., & Grant, S. (2008) · Blood · doi:10.1182/blood-2007-10-116376 · Cited by 63
Self-citationKoprinarova, M., Botev, P., & Russev, G. C. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.07.003 · Cited by 63
Jóna, Á., Khaskhely, N. M., Buglio, D., Shafer, J. A., Derenzini, E., Bollard, C. M., Medeiros, L. J., Illés, Á., Ji, Y., & Younes, A. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.07.002 · Cited by 62
Nawrocki, S. T., Carew, J. S., Douglas, L., Cleveland, J. L., Humphreys, R. C., & Houghton, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0812 · Cited by 62
Al‐Yacoub, N., Fecker, L. F., Möbs, M., Plötz, M., Braun, F., Sterry, W., & Eberle, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.125 · Cited by 61
The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage
Wang, H., Zhou, W., Zheng, Z., Zhang, P., Tu, B., He, Q., & Zhu, W. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.10.014 · Cited by 61
Santo, L., Hideshima, T., Cirstea, D., Bandi, M., Nelson, E., Gorgun, G., Rodig, S., Vallet, S., Pozzi, S., Patel, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3012 · Cited by 61
Dai, Y., Chen, S., Kmieciak, M., Zhou, L., Lin, H., Pei, X., & Grant, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0902 · Cited by 60
Self-citationYaseen, A. A., Chen, S., Hock, S. K., Rosato, R. R., Dent, P., Dai, Y., & Grant, S. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079624 · Cited by 58
Self-citationRichardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Hájek, R., Špıčka, I., Dimopoulos, M. A., Moreau, P., Siegel, D. S. D., Jagannath, S., & Anderson, K. C. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.006 · Cited by 58
Kauh, J. S. W., Fan, S., Xia, M., Yue, P., Yang, L. P. H., Khuri, F. R., & Sun, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010376 · Cited by 56
Dawson, M. A., Curry, J. E., Barber, K., Beer, P. A., Graham, B. L., Lyons, J. F., Richardson, C. J., Scott, M. A., Smyth, T., Squires, M. S., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08175.x · Cited by 55
Wiegmans, A. P., Alsop, A. E., Bots, M. L., Cluse, L. A., Williams, S. P., Banks, K.-M., Ralli, R., Scott, C. L., Frenzel, A., Villunger, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3289 · Cited by 55
Rao, R., Nalluri, S., Fiskus, W. C., Savoie, A., Buckley, K. M., Ha, K., Balusu, R., Joshi, A., Coothankandaswamy, V., Tao, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0529 · Cited by 55
Gao, N., Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.002014 · Cited by 52
Self-citationMagnaghi-Jaulin, L., Éot-Houllier, G., Fulcrand, G., & Jaulin, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3012 · Cited by 52
Tse, A. N., Sheikh, T. N., Ho, A. L., Chou, T., & Schwartz, G. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050807 · Cited by 50
The substrates of Plk1, beyond the functions in mitosis
Liu, X. S., Song, B., & Liu, X. (2010) · Protein & Cell · doi:10.1007/s13238-010-0131-x · Cited by 49
Acetylation: A Novel Link between Double-Strand Break Repair and Autophagy
Shubassi, G., Robert, T., Vanoli, F., Minucci, S., & Foiani, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3172 · Cited by 49
Collaborative roles of γH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair
Sonoda, E., Zhao, G. Y., Kohzaki, M., Dhar, P. K., Kikuchi, K., Redon, C., Pilch, D. R., Bonner, W. M., Nakano, A., Watanabe, M., et al. (2007) · DNA Repair · doi:10.1016/j.dnarep.2006.10.025 · Cited by 47 · cited 3×
“, 2007), followed by the recruitment and assembly of RAD51 into a nucleoprotein filament, which involves RAD52, x-ray repair cross-complementing proteins (XRCC) 2 and 3 and BRCA2 (N. Liu et al., 1998; Petalcorin, Sandall, Wigley, & Boulton, 2006; Sonoda et al., 2007).”
BackgroundYazbeck, V. Y., Shafer, D. A., Perkins, E. B., Coppola, D., Sokol, L., Richards, K. L., Shea, T. C., Ruan, J., Parekh, S. S., STRAIR, R. K., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.023 · Cited by 45
Self-citationExpression of PLK1 and survivin in diffuse large B-cell lymphoma
Liu, L., Zhang, M., & Zou, P. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701615918 · Cited by 44
Histone Deacetylase Inhibitors and Rational Combination Therapies
Grant, S., & Dai, Y. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00006-9 · Cited by 44
Self-citationSanda, T., Okamoto, T., Uchida, Y., Nakagawa, H., Iida, S., Kayukawa, S., Suzuki, T., Oshizawa, T., Suzuki, T., Miyata, N., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404902 · Cited by 43
Kahali, S., Sarcar, B., Prabhu, A. H., Seto, E., & Chinnaiyan, P. (2012) · The FASEB Journal · doi:10.1096/fj.11-193706 · Cited by 42
Dai, Y., Chen, S., Wang, L., Pei, X., Funk, V. L., Kramer, L. B., Dent, P., & Grant, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.284216 · Cited by 42
Self-citationDai, Y., Rahmani, M., & Grant, S. (2003) · Cell Cycle · doi:10.4161/cc.2.5.465 · Cited by 39
Self-citationInvolvement of BH3-only proteins in hematologic malignancies
Kuroda, J., & Taniwaki, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.10.004 · Cited by 39
Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair
趙, 光. (2007) · Medical Entomology and Zoology · Cited by 39
Holkova, B., Supko, J. G., Ames, M. M., Reid, J. M., Shapiro, G. I., Perkins, E. B., Ramakrishnan, V., Tombes, M. B., Honeycutt, C., McGovern, R. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2926 · Cited by 36
Self-citationWissing, M. D., Mendonca, J., Kortenhorst, M. S. Q., Kaelber, N. S., Gonzalez, M., Kim, E., Hammers, H. J., van Diest, P. J., Carducci, M. A., & Kachhap, S. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-222893 · Cited by 33
Vaziri, S. A. J., Hill, J. E., Chikamori, K., Grabowski, D., Takigawa, N., Chawla‐Sarkar, M., Rybicki, L., Gudkov, A. V., Mekhail, T. M., Bukowski, R. M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0222 · Cited by 33
Roychowdhury, S., Baiocchi, R. A., Vourganti, S., Bhatt, D., Blaser, B. W., Freud, A. G., Chou, J., Chen, C., Xiao, J. J., Parthun, M. R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh271 · Cited by 28
Dasmahapatra, G. P., Patel, H. J., Nguyen, T., Attkisson, E., & Grant, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2799 · Cited by 27
Self-citationSugimoto, K., Sasaki, M., Isobe, Y., Tsutsui, M., Suto, H., Ando, J., Tamayose, K., Ando, M., & Oshimi, K. (2007) · Oncogene · doi:10.1038/sj.onc.1210978 · Cited by 26
Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice
Li, L., Zhang, L., Fan, J., Greenberg, K. E., Desiderio, S. V., Rassool, F. V., & Small, D. (2011) · Blood · doi:10.1182/blood-2010-05-286070 · Cited by 25
Petruccelli, L. A., Pettersson, F., Rincon, S. V. D., Guilbert, C., Licht, J. D., & Miller, W. H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1039 · Cited by 25
Holkova, B., Kmieciak, M., Bose, P., Yazbeck, V. Y., Barr, P. M., Tombes, M. B., Shrader, E., Weir-Wiggins, C., Rollins, A. D., Cebula, E., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1075019 · Cited by 24
Self-citationNovel Therapies Targeting the Apoptosis Pathway for the Treatment of Acute Myeloid Leukemia
Schimmer, A. D. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0037-x · Cited by 24
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
Watanabe, T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504710 · Cited by 15
BCL-2 Inhibitor Yields High Response in CLL and SLL
(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2013-178 · Cited by 15
Holkova, B., Kmieciak, M., Bose, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.4375.4375 · Cited by 6
Self-citation
Cited by
SCFA: mechanisms and functional importance in the gut
Martin-Gallausiaux, C., Marinelli, L., Blottière, H. M., Larraufie, P., & Lapaque, N. (2021) · Proceedings of the Nutrition Society · doi:10.1017/s0029665120006916 · Cited by 1,480
Epigenetic Determinants of Cancer
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,226
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Nogal, A., Valdes, A. M., & Menni, C. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1897212 · Cited by 917
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Metadata
- Authors
- Bose, P., Dai, Y., & Grant, S.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 143
- Issue
- 3
- Pages
- 323-336
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2064609355
- Cited by
- 280
- References
- 249
- FWCI
- 12.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.